Science & Enterprise subscription

Follow us on Twitter

  • A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is ra… https://t.co/LFNVxych8d
    about 1 hour ago
  • New post on Science and Enterprise: New Allergy Biotech Launches, Raises $10M https://t.co/x5W0TwnCBu #Science #Business
    about 1 hour ago
  • Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 inf… https://t.co/LaUrUiRmhk
    about 21 hours ago
  • New post on Science and Enterprise: Trial Set for Covid-19 Antibodies in Long-Term Care https://t.co/tF0a7CDgGr #Science #Business
    about 21 hours ago
  • The numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 a… https://t.co/AO2DxxTgF8
    about 1 day ago

Please share Science & Enterprise

Biotech Gets Small Business Funds for Universal Flu Vaccine

Vaccination (U.S. Army Corps of Engineers)

(U.S. Army Corps of Engineers)

TechnoVax Inc., a biotechnology company in Tarrytown, New York, received a grant from National Institute of Allergy and Infectious Diseases, part of National Institutes of Health, to develop a vaccine that protects against a wide assortment of flu strains. The initial award of $300,000, made under the Small Business Innovation Research (SBIR) program at NIH, covers the first year of a two-year project.

The TechnoVax technology is based on research on influenza virus-like particles by company founder and president Jose Galarza. Virus-like particles resemble native viruses, but do not contain nucleic acid, the genetic material in viruses. The lack of nucleic acid leaves the particles unable to replicate and thus are not infectious and safer to handle, but still generate an immune response .

In this project, TechnoVax proposes  reengineering hemagglutinin molecules that coat the surface of influenza viruses and bind to the cells being infected. Antibodies targeting these hemagglutinin molecules, says TechnoVax, were found to neutralize a broad spectrum of influenza viruses. Therefore, adding reengineered hemagglutinin molecules to virus-like particles should lead to a broadly neutralizing vaccine.

The research is designed to prove the concept, i.e. show the scientific merit and commercial feasibility of the process, with preclinical lab tests and animal models.The company plans to test the technique on three diverse viruses. If the results support the proposed process, TechnoVax aims to request further SBIR funding to develop a workable vaccine.

TechnoVax says its manufacturing methods do not use the current approach of most vaccine producers of infecting eggs with live viruses to produce vaccines, but rather make use of cell cultures that can produce a wide variety of vaccines. The cell method, says the company, produces vaccines that generate a strong immune response, yet because the virus-like particles are non-infectious, their methods are safer and work faster than the infected egg method.

Read more:

*     *     *

1 comment to Biotech Gets Small Business Funds for Universal Flu Vaccine